A Pilot Study on the Utility of Serum Metabolomics in Neuroblastoma Patients and Xenograft Models-Reference-Cited by-同舟云学术

A Pilot Study on the Utility of Serum Metabolomics in Neuroblastoma Patients and Xenograft Models

Published:2015-10-20 Issue:2 Volume:63 Page:214-220
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Beaudry Paul¹,Campbell Martin²,Dang N. Ha³,Wen Jing⁴,Blote Karen¹,Weljie Aalim M.³⁵

Affiliation:

1. Division of Pediatric Surgery; Alberta Children's Hospital; Calgary Canada

2. Children's Cancer Centre; Royal Children's Hospital; Melbourne Australia

3. Department of Oncology, University of Calgary; Canada

4. Department of Biological Sciences, University of Calgary; Canada

5. Department of Systems Pharmacology and Translational Therapeutics; University of Pennsylvania; Philadelphia Pennsylvania

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Reference28 articles.

1. Neuroblastoma;Maris;Lancet,2007

2. Aggressive surgical therapy and radiotherapy for patients with high-risk neuroblastoma treated with rapid sequence tandem transplant;Allmen;J Pediatr Surg,2005

3. Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: Results of children's oncology group study P9641;Strother;J Clin Oncol,2012

4. Progress in treatment and risk stratification of neuroblastoma: Impact on future clinical and basic research;Ora;Semin Cancer Biol,2011

5. Response and toxicity to a dose-intensive multi-agent chemotherapy induction regimen for high risk neuroblastoma (HR-NB): A Children's Oncology Group (COG A3973) study;Kreissman;J Clin Oncol,2007

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Joint metabolomics and transcriptomics analysis systematically reveal the impact of MYCN in neuroblastoma;Scientific Reports;2024-08-30

2. Metabolomics-transcriptomics joint analysis: unveiling the dysregulated cell death network and developing a diagnostic model for high-grade neuroblastoma;Frontiers in Immunology;2024-01-04

3. Joint analysis of the metabolomics and transcriptomics uncovers the dysregulated network and develops the diagnostic model of high-risk neuroblastoma;Scientific Reports;2023-10-09

4. Untargeted LC-HRMS Based-Plasma Metabolomics Reveals 3-O-Methyldopa as a New Biomarker of Poor Prognosis in High-Risk Neuroblastoma;Frontiers in Oncology;2022-06-10

5. Metabolomic profiling in neuroblastoma;Pediatric Blood & Cancer;2019-12-04